EUCTR2007-003156-11-IT进行中（未招募）不适用
Trastuzumab, docetaxel and gemcitabine as first line treatment for HER-2 positive advanced breast cancer: a phase II of G.O.I.M. - ND
GOIM GRUPPO ONCOLOGICO MERIDIONALE0 个研究点开始时间: 2007年9月10日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •histologically confirmed metastatic breast cancer, tumor overexpressing HER2/neu (+++)or with HER2/neu
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •previous chemiotherapy for metastatic disease, concomitant serious diseases (cardiovascular, renal etc.), preesistent neuropathy
研究者
相似试验
尚未招募
不适用
First-line trastuzumab, gemcitabine, cisplatin and nivolumab in advanced HER2-positive biliary tract cancer: a multicenter, openlabel, single-arm phase Ib/II trial (HERBOT)KCT0008250Yonsei University Health System, Severance Hospital44
尚未招募
不适用
eoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in HER2-positive breast cancer: the TRAIN-4 studyBreast cancerNL-OMON53609Antoni van Leeuwenhoek Ziekenhuis30
进行中（未招募）
1 期
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancer.Women with a diagnosis of non-metastatic high-risk invasive unilateral, HER2-positive breast cancer.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000981-31-BEFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650
进行中（未招募）
1 期
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancer.EUCTR2017-000981-31-ATFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650
进行中（未招募）
1 期
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant (before surgery) treatment of HER2 positive early high-risk and locally advanced breast cancerWomen with a diagnosis of non metastatic high-risk invasive unilateral, HER2-positive breast cancerMedDRA version: 20.0Level: LLTClassification code 10006283Term: Breast neoplasm malignant femaleSystem Organ Class: 100000004864EUCTR2017-000981-31-ITFONDAZIONE MICHELANGELO ONLUS PER L'AVANZAMENTO DELLO STUDIO E LA CURA DEI TUMORI650